Fusobacterium nucleatum enhances CRC aggressiveness and EMT in DSS-treated cells. In mouse models, F. nucleatum increases malignancy in AOM/DSS-induced colon cancer. EGFR inhibition reduces F. nucleatum-induced EMT alteration. F. nucleatum accelerates CAC progression by activating the EGFR signaling pathway. This evidence concerns the gene EGFR and malignant colon neoplasm.